The yield on the US 10-Year Treasury Note reached 1.808% yesterday, its highest level since January 2020 (pre-pandemic). However, this isn’t the only yield in town making new highs. Today, the German Bund reached a Read more…
If stops below 1.2600 are triggered, the pair could be at the next support level in a hurry. USD/CAD is close to a key level of 1.2600, which if broken, could set the stage for Read more…
NZDCHF reversed key resistance level 0.6275 Likely to fall to support level 0.6177 NZDCHF recently reversed down from the powerful resistance level 0.6275 (which has been reversing the price from the start of December), intersecting Read more…
What is happening? In December 2021, the main question on global markets was: “When will the FED increase the key rate?” Traders and investors were transferring their capitals into USDs, waiting for the great dump Read more…
Or further to go? It’s been a shaky start to the new year, with interest rate anxieties dragging on sentiment and hitting the NAS100 particularly hard. The index fell more than 8% over the last Read more…
“We didn’t get it to quite where we needed to get it,” Fed Chairman Jerome Powell said at his confirmation hearing. A long-awaited report exploring the benefits of cryptocurrency and a possible central bank digital Read more…
Shake Shack’s total revenue and sales both grew 34% in the fourth quarter compared to the same period in 2019, according to an unaudited report. Shake Shack (SHAK) – Get Shake Shack, Inc. Class A Read more…
Two prototypes, equipped with fingerprint readers and chips, are currently being tested and could hit the market this year. But the gun lobby is watching. Smart guns, equipped with fingerprint readers, passcodes and a way Read more…
Jim Cramer says whether things are going right or wrong, discerning investors can always find great names to buy on weakness. Sometimes, there’s just too much good news to ignore, Jim Cramer told his Mad Read more…
Biogen said that the decision “will exclude almost all patients who may benefit.” A controversial new drug used to treat Alzheimer’s will only be covered by Medicare if patients are in clinical trials. On Tuesday, Read more…